Robotic Brachytherapy and Sublobar Resection for T1 Non-Small Cell Lung Cancer in High-Risk Patients

被引:6
|
作者
Blasberg, Justin D. [1 ]
Belsley, Scott J.
Schwartz, Gary S.
Evans, Andrew
Wernick, Iddo
Ashton, Robert C., Jr.
Bhora, Faiz Y.
Connery, Cliff P.
机构
[1] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Dept Surg, New York, NY 10023 USA
来源
ANNALS OF THORACIC SURGERY | 2010年 / 89卷 / 02期
关键词
THORACOSCOPIC WEDGE RESECTION; LIMITED RESECTION; I-125; BRACHYTHERAPY; LOBECTOMY; SEGMENTECTOMY; CARCINOMA; PULMONARY; SURVIVAL; IMPLANTATION;
D O I
10.1016/j.athoracsur.2009.09.052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Sublobar lung resection and brachytherapy seed placement is gaining acceptance for T1 non-small cell lung cancer (NSCLC) in select patients with comorbidities precluding lobectomy. Our institution first reported utilization of the da Vinci system for robotic brachytherapy developed experimentally in swine and applied to high-risk patients 5 years ago. We now report seed dosimetrics and midterm follow-up. Methods. Eleven high-risk patients with stage IA NSCLC who were not candidates for conventional lobectomy underwent limited resection of 12 primary tumors. To reduce locoregional recurrence, I-125 brachytherapy seeds were robotically sutured intracorporeally over resection margins to deliver 14,400 cGy 1 cm from the implant plane. Patients were followed with dosimetric computed tomography scans at 30 +/- 16 days. Survival and sites of recurrence were documented. Results. Resected tumor size averaged 1.48 +/- 0.38 cm (range, 1.1 to 2.1 cm). Perioperative mortality was 0% and recurrence was 9% (1 of 11 [margin recurrence at 6 months with resultant mortality at 1 year]). Follow-up duration was 31.82 +/- 17.35 months. Dosimetrics confirmed 14,400 cGy delivery using 24.21 +/- 4.6 I-125 seeds (range, 17 to 30 seeds) over a planning target volume of 10.29 +/- 2.39 cc(3). Overall, 84.1% of the planning target volume was covered by 100% of the prescription dose (V100), and 88.2% was covered by 87% of the prescription dose (V87), comparable to open dosimetric data at our institution. Follow-up imaging confirmed seed stability in all patients. Conclusions. Robotic I-125 brachytherapy seed placement is a feasible adjuvant procedure to reduce the incidence of recurrence after sublobar resection in medically compromised patients. Tailored robotic seed placement delivers an exact dosing regimen in a minimally invasive fashion with equivalent precision to open surgery. (Ann Thorac Surg 2010;89:360-7) (C) 2010 by The Society of Thoracic Surgeons
引用
收藏
页码:360 / 367
页数:8
相关论文
共 50 条
  • [21] Sublobar Resection for Non-Small Cell Lung Cancer in Octogenarians: A Prospective, Multicenter Study
    Mimae, Takahiro
    Saji, Hisashi
    Nakamura, Hiroshige
    Okumura, Norihito
    Tsuchida, Masanori
    Sonobe, Makoto
    Miyazaki, Takuro
    Aokage, Keiju
    Nakao, Masayuki
    Haruki, Tomohiro
    Okada, Morihito
    Suzuki, Kenji
    Yoshino, Ichiro
    ANNALS OF THORACIC SURGERY, 2023, 116 (03): : 543 - 551
  • [22] Robotic Lung Resection for Non-Small Cell Lung Cancer
    Wei, Benjamin
    Eldaif, Shady M.
    Cerfolio, Robert J.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 25 (03) : 515 - +
  • [23] Comparison Between Stereotactic Radiotherapy and Sublobar Resection for Non-Small Cell Lung Cancer
    Tamura, Masaya
    Matsumoto, Isao
    Tanaka, Yusuke
    Saito, Daisuke
    Yoshida, Shuhei
    Kakegawa, Seiichi
    Kumano, Tomoyasu
    Shimizu, Yosuke
    Tamamura, Hiroyasu
    Takanaka, Tsuyoshi
    Takemura, Hirofumi
    ANNALS OF THORACIC SURGERY, 2019, 107 (05): : 1544 - 1551
  • [24] Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate choice in elderly patients?
    Fiorelli, Alfonso
    Caronia, Francesco Paolo
    Daddi, Niccolo
    Loizzi, Domenico
    Ampollini, Luca
    Ardo, Nicoletta
    Ventura, Luigi
    Carbognani, Paolo
    Potenza, Rossella
    Ardissone, Francesco
    Sollitto, Francesco
    Mattioli, Sandro
    Puma, Francesco
    Santini, Mario
    Ragusa, Mark
    SURGERY TODAY, 2016, 46 (12) : 1370 - 1382
  • [25] Segmentectomy versus wedge resection for the treatment of high-risk operable patients with stage I non-small cell lung cancer: a meta-analysis
    Hou, Bing
    Deng, Xu-Feng
    Zhou, Dong
    Liu, Quan-Xing
    Dai, Ji-Gang
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (05) : 435 - 443
  • [26] Spread Through Air Spaces Is a Prognostic Factor in Sublobar Resection of Non-Small Cell Lung Cancer
    Shiono, Satoshi
    Endo, Makoto
    Suzuki, Katsuyuki
    Yarimizu, Kei
    Hayasaka, Kazuki
    Yanagawa, Naoki
    ANNALS OF THORACIC SURGERY, 2018, 106 (02): : 354 - 360
  • [27] Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer
    Altorki, Nasser
    Wang, Xiaofei
    Kozono, David
    Watt, Colleen
    Landrenau, Rodney
    Wigle, Dennis
    Port, Jeffrey
    Jones, David R.
    Conti, Massimo
    Ashrafi, Ahmad S.
    Liberman, Moishe
    Yasufuku, Kazuhiro
    Yang, Stephen
    Mitchell, John D.
    Pass, Harvey
    Keenan, Robert
    Bauer, Thomas
    Miller, Daniel
    Kohman, Leslie J.
    Stinchcombe, Thomas E.
    Vokes, Everett
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (06): : 489 - 498
  • [28] The Role of Sublobar Resection in Early-Stage Non-Small-Cell Lung Cancer
    Petrella, Francesco
    Cara, Andrea
    Cassina, Enrico Mario
    Degiovanni, Sara
    Libretti, Lidia
    Pirondini, Emanuele
    Raveglia, Federico
    Tuoro, Antonio
    Vaquer, Sara
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [29] Sublobar resection is equivalent to lobectomy for T1a non-small cell lung cancer in the elderly: a Surveillance, Epidemiology, and End Results database analysis
    Razi, Syed S.
    John, Mohan M.
    Sainathan, Sandeep
    Stavropoulos, Christos
    JOURNAL OF SURGICAL RESEARCH, 2016, 200 (02) : 683 - 689
  • [30] Sublobar Resection Ongoing Controversy for Treatment for Stage I Non-Small Cell Lung Cancer
    Sesti, Joanna
    Donington, Jessica S.
    THORACIC SURGERY CLINICS, 2016, 26 (03) : 251 - +